Dr. Fadi Braiteh, MD
Claim this profileComprehensive Cancer Centers of Nevada
Studies Cancer
Studies Solid Tumors
19 reported clinical trials
34 drugs studied
About Fadi Braiteh, MD
Education:
- Graduated with an MD from the American University of Beirut Faculty of Medicine, Lebanon, in 1996.
- Completed a Residency in Internal Medicine at the University of Nevada School of Medicine in 2000.
- Finished a Fellowship in Hematology/Oncology at the University of Nevada School of Medicine in 2003.
Experience:
- Currently serves as a medical oncologist and hematologist at Comprehensive Cancer Centers of Nevada.
Area of expertise
1Cancer
Stage IV
Stage III
metastatic
2Solid Tumors
Stage IV
BRAF positive
Stage III
Affiliated Hospitals
Clinical Trials Fadi Braiteh, MD is currently running
BT8009 + Pembrolizumab
for Solid Tumors
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Parts B1-B7), Safety and tolerability (Parts B-8, B-9 and C), and characterization of the pharmacokinetics (Part D).
Recruiting1 award Phase 1 & 214 criteria
Tazemetostat
for Advanced Cancer with Liver Impairment
This trial tests tazemetostat, an oral medication, in patients with advanced solid tumors and different liver functions. It aims to understand how the drug behaves in the body and its safety. Researchers will measure drug levels in the blood and monitor for side effects. Tazemetostat is approved by the FDA for certain types of cancer.
Recruiting1 award Phase 1
More about Fadi Braiteh, MD
Clinical Trial Related6 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Fadi Braiteh, MD has experience with
- Pembrolizumab
- PD-1 Inhibitor
- Nivolumab
- ABM-1310
- Cobimetinib
- CAB-ROR2-ADC
Breakdown of trials Fadi Braiteh, MD has run
Cancer
Solid Tumors
Breast Cancer
Head and Neck Cancers
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Fadi Braiteh, MD specialize in?
Fadi Braiteh, MD focuses on Cancer and Solid Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Fadi Braiteh, MD currently recruiting for clinical trials?
Yes, Fadi Braiteh, MD is currently recruiting for 5 clinical trials in Las Vegas Nevada. If you're interested in participating, you should apply.
Are there any treatments that Fadi Braiteh, MD has studied deeply?
Yes, Fadi Braiteh, MD has studied treatments such as Pembrolizumab, PD-1 inhibitor, Nivolumab.
What is the best way to schedule an appointment with Fadi Braiteh, MD?
Apply for one of the trials that Fadi Braiteh, MD is conducting.
What is the office address of Fadi Braiteh, MD?
The office of Fadi Braiteh, MD is located at: Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada 89169 United States. This is the address for their practice at the Comprehensive Cancer Centers of Nevada.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.